vs

Side-by-side financial comparison of TRUSTMARK CORP (TRMK) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

TRUSTMARK CORP is the larger business by last-quarter revenue ($204.1M vs $127.1M, roughly 1.6× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 4.5%). TRUSTMARK CORP produced more free cash flow last quarter ($232.0M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 8.9%).

Trustmark is an insurance company. According to Crain's Chicago Business magazine, Trustmark ranks #69 among Chicago's Largest Privately Held Companies in 2018.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

TRMK vs ZLAB — Head-to-Head

Bigger by revenue
TRMK
TRMK
1.6× larger
TRMK
$204.1M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+12.6% gap
ZLAB
17.1%
4.5%
TRMK
More free cash flow
TRMK
TRMK
$258.7M more FCF
TRMK
$232.0M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
8.9%
TRMK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TRMK
TRMK
ZLAB
ZLAB
Revenue
$204.1M
$127.1M
Net Profit
$57.9M
Gross Margin
51.0%
Operating Margin
34.7%
-54.6%
Net Margin
28.4%
Revenue YoY
4.5%
17.1%
Net Profit YoY
2.8%
EPS (diluted)
$0.96
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$204.1M
$127.1M
Q3 25
$202.4M
$115.4M
Q2 25
$198.6M
$109.1M
Q1 25
$194.6M
$105.7M
Q4 24
$155.8M
$108.5M
Q3 24
$192.3M
$101.8M
Q2 24
$141.0M
$100.1M
Q1 24
$172.2M
$87.1M
Net Profit
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$57.9M
Q3 25
$56.8M
$-36.0M
Q2 25
$55.8M
$-40.7M
Q1 25
$53.6M
$-48.4M
Q4 24
$56.3M
Q3 24
$51.3M
$-41.7M
Q2 24
$73.8M
$-80.3M
Q1 24
$41.5M
$-53.5M
Gross Margin
TRMK
TRMK
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
TRMK
TRMK
ZLAB
ZLAB
Q4 25
34.7%
-54.6%
Q3 25
34.5%
-42.3%
Q2 25
34.7%
-50.3%
Q1 25
33.6%
-53.3%
Q4 24
41.6%
-62.6%
Q3 24
32.5%
-66.6%
Q2 24
-98.1%
-76.0%
Q1 24
26.1%
-80.7%
Net Margin
TRMK
TRMK
ZLAB
ZLAB
Q4 25
28.4%
Q3 25
28.1%
-31.2%
Q2 25
28.1%
-37.3%
Q1 25
27.6%
-45.8%
Q4 24
36.1%
Q3 24
26.7%
-40.9%
Q2 24
52.4%
-80.2%
Q1 24
24.1%
-61.4%
EPS (diluted)
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$0.96
$-0.05
Q3 25
$0.94
$-0.03
Q2 25
$0.92
$-0.04
Q1 25
$0.88
$-0.04
Q4 24
$0.91
$-0.09
Q3 24
$0.84
$-0.04
Q2 24
$1.20
$-0.08
Q1 24
$0.68
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TRMK
TRMK
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.1B
$715.5M
Total Assets
$18.9B
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$630.0M
Q1 24
$650.8M
Stockholders' Equity
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$2.1B
$715.5M
Q3 25
$2.1B
$759.9M
Q2 25
$2.1B
$791.7M
Q1 25
$2.0B
$810.8M
Q4 24
$2.0B
$840.9M
Q3 24
$2.0B
$667.7M
Q2 24
$1.9B
$704.2M
Q1 24
$1.7B
$762.2M
Total Assets
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$18.9B
$1.2B
Q3 25
$18.8B
$1.2B
Q2 25
$18.6B
$1.2B
Q1 25
$18.3B
$1.2B
Q4 24
$18.2B
$1.2B
Q3 24
$18.5B
$985.3M
Q2 24
$18.5B
$987.4M
Q1 24
$18.4B
$988.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TRMK
TRMK
ZLAB
ZLAB
Operating Cash FlowLast quarter
$243.9M
$-26.0M
Free Cash FlowOCF − Capex
$232.0M
$-26.7M
FCF MarginFCF / Revenue
113.6%
-21.0%
Capex IntensityCapex / Revenue
5.9%
0.5%
Cash ConversionOCF / Net Profit
4.21×
TTM Free Cash FlowTrailing 4 quarters
$409.8M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$243.9M
$-26.0M
Q3 25
$66.2M
$-32.0M
Q2 25
$37.6M
$-31.0M
Q1 25
$82.4M
$-61.7M
Q4 24
$116.9M
$-55.8M
Q3 24
$59.5M
$-26.8M
Q2 24
$16.7M
$-42.2M
Q1 24
$-58.5M
$-90.1M
Free Cash Flow
TRMK
TRMK
ZLAB
ZLAB
Q4 25
$232.0M
$-26.7M
Q3 25
$62.7M
$-35.0M
Q2 25
$34.5M
$-33.9M
Q1 25
$80.6M
$-63.2M
Q4 24
$93.4M
$-58.4M
Q3 24
$51.2M
$-28.2M
Q2 24
$10.5M
$-42.9M
Q1 24
$-63.6M
$-91.1M
FCF Margin
TRMK
TRMK
ZLAB
ZLAB
Q4 25
113.6%
-21.0%
Q3 25
31.0%
-30.4%
Q2 25
17.4%
-31.1%
Q1 25
41.4%
-59.9%
Q4 24
60.0%
-53.8%
Q3 24
26.7%
-27.7%
Q2 24
7.4%
-42.9%
Q1 24
-36.9%
-104.5%
Capex Intensity
TRMK
TRMK
ZLAB
ZLAB
Q4 25
5.9%
0.5%
Q3 25
1.8%
2.6%
Q2 25
1.6%
2.6%
Q1 25
0.9%
1.5%
Q4 24
15.1%
2.4%
Q3 24
4.3%
1.3%
Q2 24
4.4%
0.7%
Q1 24
2.9%
1.1%
Cash Conversion
TRMK
TRMK
ZLAB
ZLAB
Q4 25
4.21×
Q3 25
1.17×
Q2 25
0.67×
Q1 25
1.54×
Q4 24
2.08×
Q3 24
1.16×
Q2 24
0.23×
Q1 24
-1.41×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TRMK
TRMK

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons